RAMASWAMI, U., M. FUTEMA, M. P. BOGSRUD, K. B. HOLVEN, J. R. VAN LENNEP, A. WIEGMAN, O. S. DESCAMPS, M. VRABLIK, Tomáš FREIBERGER, H. DIEPLINGER, S. GREBER-PLATZER, G. HANAUER-MADER, M. BOURBON, E. DROGARI and S. E. HUMPHRIES. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. Clare: ELSEVIER SCI IRELAND LTD, 2020, vol. 292, JAN 2020, p. 178-187. ISSN 0021-9150. Available from: https://dx.doi.org/10.1016/j.atherosclerosis.2019.11.012.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
Authors RAMASWAMI, U. (826 United Kingdom of Great Britain and Northern Ireland), M. FUTEMA (826 United Kingdom of Great Britain and Northern Ireland), M. P. BOGSRUD (578 Norway), K. B. HOLVEN (578 Norway), J. R. VAN LENNEP (528 Netherlands), A. WIEGMAN (528 Netherlands), O. S. DESCAMPS (56 Belgium), M. VRABLIK (203 Czech Republic), Tomáš FREIBERGER (203 Czech Republic, belonging to the institution), H. DIEPLINGER (40 Austria), S. GREBER-PLATZER (40 Austria), G. HANAUER-MADER (40 Austria), M. BOURBON (620 Portugal), E. DROGARI (300 Greece) and S. E. HUMPHRIES (826 United Kingdom of Great Britain and Northern Ireland, guarantor).
Edition Atherosclerosis, Clare, ELSEVIER SCI IRELAND LTD, 2020, 0021-9150.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.162
RIV identification code RIV/00216224:14110/20:00115978
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.atherosclerosis.2019.11.012
UT WoS 000503400300024
Keywords in English Heterozygous familial hypercholesterolaemia; Paediatric FH; LDL-C concentrations; Statin treatment
Tags 14110114, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 15/7/2020 08:10.
Abstract
Background and aims: For children with heterozygous familial hypercholesterolaemia (HeFH), European guidelines recommend consideration of statin therapy by age 8-10 years for those with a low density lipoprotein cholesterol (LDL-C) > 3.5 mmol/l, and dietary and lifestyle advice. Here we compare the characteristics and lipid levels in HeFH children from Norway, UK, Netherlands, Belgium, Czech Republic, Austria, Portugal and Greece. Methods: Fully-anonymized data were analysed at the London centre. Differences in registration and on treatment characteristics were compared by standard statistical tests. Results: Data was obtained from 3064 children. The median age at diagnosis differed significantly between countries (range 3-11 years) reflecting differences in diagnostic strategies. Mean (SD) LDL-C at diagnosis was 5.70 (+/- 1.4) mmol/l, with 88% having LDL-C > 4.0 mmol/l. The proportion of children older than 10 years at follow-up who were receiving statins varied significantly (99% in Greece, 56% in UK), as did the proportion taking Ezetimibe (0% in UK, 78% in Greece). Overall, treatment reduced LDL-C by between 28 and 57%, however, in those > 10 years, 23% of on-treatment children still had LDL-C > 3.5 mmol/l and 66% of those not on a statin had LDL-C > 3.5 mmol/l. Conclusions: The age of HeFH diagnosis in children varies significantly across 8 countries, as does the proportion of those > 10 years being treated with statin and/or ezetimibe. Approximately a quarter of the treated children and almost three quarters of the untreated children older than 10 years still have LDL-C concentrations over 3.5 mmol/l. These data suggest that many children with FH are not receiving the full potential benefit of early identification and appropriate lipid-lowering treatment according to recommendations.
PrintDisplayed: 26/4/2024 19:55